Mia's Feed
Medical News & Research

Potential of Glycoprotein Reelin in Treating Leaky Gut and Severe Depression

Potential of Glycoprotein Reelin in Treating Leaky Gut and Severe Depression

Share this article

Research from the University of Victoria suggests that the glycoprotein reelin may offer new hope for treating both leaky gut syndrome and severe depression by restoring gut integrity and improving mood symptoms.

2 min read

Recent research from the University of Victoria highlights the promising role of a glycoprotein called reelin in addressing both 'leaky gut' syndrome and severe depression. Chronic stress and related psychiatric conditions can impair the gut barrier's integrity, leading to increased permeability, commonly known as leaky gut. This condition allows harmful bacteria and toxins to enter circulation, triggering immune responses and inflammation that may worsen depressive symptoms.

The study, published in Chronic Stress, investigated how reelin, a protein present throughout the body—including in the brain, blood, liver, and intestines—may restore gut health and alleviate depression. Findings revealed that chronic stress decreases reelin levels in the intestines of preclinical models, but a single injection of 3 micrograms of reelin successfully normalized these levels.

This is significant because lower reelin levels have been observed in individuals with major depressive disorder (MDD) and in stressed rodents. Notably, reelin injections have shown antidepressant-like effects and support gut lining renewal. Given that the gut lining is renewed every four to five days under healthy conditions, reelin’s protective role could prevent the progression of leaky gut and subsequent inflammatory responses that exacerbate depression.

Professor Hector Caruncho explained that reelin's presence in the gut-brain axis positions it as a potential therapeutic candidate for psychiatric disorders linked to gastrointestinal health. While further research is necessary before reelin becomes part of clinical treatment, these findings suggest that targeting reelin could offer a dual approach to managing depression and gastrointestinal conditions, especially for individuals suffering from both.

This groundbreaking research emphasizes the interconnectedness of gut health and mental health, proposing a novel pathway for therapies that support both physical and psychological well-being.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Integrating Self-Monitoring, Coaching, and Wearable Devices to Enhance Sleep and Reduce Alcohol Consumption in Young Adults

A novel digital health program leveraging self-monitoring, coaching, and wearables effectively improves sleep and reduces risky alcohol consumption in young adults, offering a scalable solution to a significant public health issue.

Large-Scale Study Finds No Increased Risk of Guillain-Barré Syndrome from mRNA COVID-19 Vaccines

A global study involving over 230 million people confirms that mRNA COVID-19 vaccines do not increase the risk of Guillain-Barré syndrome, while highlighting the higher risk associated with COVID-19 infection itself. Continuous safety monitoring supports the importance of vaccination in pandemic control.

Rising Alcohol-Related Cancer Deaths in the United States

A new study highlights the alarming rise in alcohol-related cancer deaths in the US, emphasizing the need for increased awareness and preventative strategies to combat this growing health threat.

CDC Approves RSV Vaccine for Adults Aged 50 and Older with Certain Health Conditions

The CDC has expanded its guidelines to include RSV vaccination for adults aged 50 and older with certain health risks, aiming to prevent severe respiratory illness in vulnerable populations.